Published in Clin Cancer Res on July 18, 2012
Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease. Dig Dis Sci (2013) 1.48
Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol (2015) 1.33
Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer (2012) 1.32
Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas. Oncotarget (2014) 1.08
YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression. Cell Rep (2015) 1.08
Liver cancer: Approaching a personalized care. J Hepatol (2015) 1.05
SERPINB3 is associated with TGF-β1 and cytoplasmic β-catenin expression in hepatocellular carcinomas with poor prognosis. Br J Cancer (2014) 1.03
Transcriptome profiling of archived sectioned formalin-fixed paraffin-embedded (AS-FFPE) tissue for disease classification. PLoS One (2014) 1.01
Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells. Oncotarget (2015) 0.95
Notch and Wnt/β-catenin signaling pathway play important roles in activating liver cancer stem cells. Oncotarget (2016) 0.91
PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation. Oncogene (2015) 0.89
Form and Function: how Estrogen and Progesterone Regulate the Mammary Epithelial Hierarchy. J Mammary Gland Biol Neoplasia (2015) 0.88
Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment. World J Gastroenterol (2016) 0.88
Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma. World J Gastroenterol (2016) 0.88
Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients. Oncotarget (2015) 0.85
Using activation status of signaling pathways as mechanism-based biomarkers to predict drug sensitivity. Sci Rep (2015) 0.85
EpCAM-regulated intramembrane proteolysis induces a cancer stem cell-like gene signature in hepatitis B virus-infected hepatocytes. J Hepatol (2016) 0.84
Genetic alterations in hepatocellular carcinoma: An update. World J Gastroenterol (2016) 0.83
Role of leukocyte cell-derived chemotaxin 2 as a biomarker in hepatocellular carcinoma. PLoS One (2014) 0.83
NDRG1 promotes growth of hepatocellular carcinoma cells by directly interacting with GSK-3β and Nur77 to prevent β-catenin degradation. Oncotarget (2015) 0.81
Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis? World J Gastrointest Oncol (2016) 0.80
ALDH3A1 is overexpressed in a subset of hepatocellular carcinoma characterised by activation of the Wnt/ß-catenin pathway. Virchows Arch (2013) 0.79
Transcript profiling identifies iqgap2(-/-) mouse as a model for advanced human hepatocellular carcinoma. PLoS One (2013) 0.79
Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. F1000Res (2016) 0.78
High Expression of miR-532-5p, a Tumor Suppressor, Leads to Better Prognosis in Ovarian Cancer Both In Vivo and In Vitro. Mol Cancer Ther (2016) 0.78
Reversible Human TGF-β Signal Shifting between Tumor Suppression and Fibro-Carcinogenesis: Implications of Smad Phospho-Isoforms for Hepatic Epithelial-Mesenchymal Transitions. J Clin Med (2016) 0.78
Secreted frizzled‑related protein 2 is epigenetically silenced and functions as a tumor suppressor in oral squamous cell carcinoma. Mol Med Rep (2014) 0.78
The orthologous Tbx transcription factors Omb and TBX2 induce epithelial cell migration and extrusion in vivo without involvement of matrix metalloproteinases. Oncotarget (2014) 0.78
Human breast progenitor cell numbers are regulated by WNT and TBX3. PLoS One (2014) 0.78
De novo HAPLN1 expression hallmarks Wnt-induced stem cell and fibrogenic networks leading to aggressive human hepatocellular carcinomas. Oncotarget (2016) 0.78
Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment. Liver Cancer (2016) 0.78
CWP232228 targets liver cancer stem cells through Wnt/β-catenin signaling: a novel therapeutic approach for liver cancer treatment. Oncotarget (2016) 0.77
The role of Wnt signaling pathway in carcinogenesis and implications for anticancer therapeutics. Hered Cancer Clin Pract (2014) 0.77
A review on the diagnosis and treatment of hepatocellular carcinoma with a focus on the role of Wnts and the dickkopf family of Wnt inhibitors. J Hepatocell Carcinoma (2014) 0.76
Aberrant regulation of Wnt signaling in hepatocellular carcinoma. World J Gastroenterol (2016) 0.76
Diverse Basis of β-Catenin Activation in Human Hepatocellular Carcinoma: Implications in Biology and Prognosis. PLoS One (2016) 0.76
Efficacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules. Transl Cancer Res (2013) 0.76
Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. Gut (2016) 0.76
Systemic treatment for hepatocellular carcinoma: Still unmet expectations. World J Hepatol (2017) 0.75
Immune targeting of cancer stem cells in gastrointestinal oncology. J Gastrointest Oncol (2016) 0.75
Chemical inhibition reveals differential requirements of signaling pathways in kras(V12)- and Myc-induced liver tumors in transgenic zebrafish. Sci Rep (2017) 0.75
Effect of Ginkgo biloba extract on the expressions of Cox-2 and GST-Pi in rats with hepatocellular carcinoma risk. Afr Health Sci (2014) 0.75
Prognostic value of DNA repair based stratification of hepatocellular carcinoma. Sci Rep (2016) 0.75
Histopathological characteristics of glutamine synthetase-positive hepatic tumor lesions in a mouse model of spontaneous metabolic syndrome (TSOD mouse). Mol Clin Oncol (2016) 0.75
Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives. J Hepatocell Carcinoma (2014) 0.75
Action and function of Wnt/β-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma. J Gastroenterol (2016) 0.75
Identification of the β-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells. Oncotarget (2015) 0.75
A validated, transitional and translational porcine model of hepatocellular carcinoma. Oncotarget (2017) 0.75
β-catenin alteration is rare in hepatocellular carcinoma with steatohepatitic features: immunohistochemical and mutational study. Virchows Arch (2015) 0.75
Evolving role of Sorafenib in the management of hepatocellular carcinoma. World J Clin Oncol (2017) 0.75
Role of the Transforming Growth Factor-β in regulating hepatocellular carcinoma oxidative metabolism. Sci Rep (2017) 0.75
Paracrine and autocrine regulation of gene expression by Wnt-inhibitor Dickkopf in wild-type and mutant hepatocytes. BMC Syst Biol (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res (2000) 117.00
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
GenePattern 2.0. Nat Genet (2006) 29.07
More powerful procedures for multiple significance testing. Stat Med (1990) 17.12
Wnt signalling and its impact on development and cancer. Nat Rev Cancer (2008) 8.37
Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol (1996) 6.88
MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology (2008) 5.28
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology (2007) 4.73
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res (2008) 4.17
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology (2007) 3.18
Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res (2007) 2.63
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
Wnt signalling: variety at the core. J Cell Sci (2007) 2.23
Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin Cancer Biol (2010) 1.91
Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology (2004) 1.88
Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene (2006) 1.84
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77
Nearest template prediction: a single-sample-based flexible class prediction with confidence assessment. PLoS One (2010) 1.65
Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer (2008) 1.59
Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells. Mol Cancer (2009) 1.44
Analysis of endogenous LRP6 function reveals a novel feedback mechanism by which Wnt negatively regulates its receptor. Mol Cell Biol (2007) 1.40
Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother (2010) 1.29
Liver zonation occurs through a beta-catenin-dependent, c-Myc-independent mechanism. Gastroenterology (2009) 1.25
P53 mutation as a source of aberrant beta-catenin accumulation in cancer cells. Oncogene (2002) 1.14
Inactivation of PI3K/AKT signaling inhibits glioma cell growth through modulation of β-catenin-mediated transcription. Brain Res (2010) 1.02
Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line. Int J Clin Exp Pathol (2010) 0.99
Essential requirement for β-arrestin2 in mouse intestinal tumors with elevated Wnt signaling. Proc Natl Acad Sci U S A (2012) 0.95
FRAT1 and FRAT2, clustered in human chromosome 10q24.1 region, are up-regulated in gastric cancer. Int J Oncol (2001) 0.93
Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers. Clin Cancer Res (2011) 0.92
Wnt-β-catenin-Tcf-4 signalling-modulated invasiveness is dependent on osteopontin expression in breast cancer. Br J Cancer (2011) 0.90
Molecular cloning and characterization of FRAT2, encoding a positive regulator of the WNT signaling pathway. Biochem Biophys Res Commun (2001) 0.87
Aberrant expression and function of TCF4 in the proliferation of hepatocellular carcinoma cell line BEL-7402. Cell Res (2004) 0.86
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Hepatocellular carcinoma. Lancet (2003) 22.54
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Hepatocellular carcinoma. Lancet (2012) 18.09
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (2002) 12.16
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (2003) 11.55
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis (2010) 9.73
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature (2011) 8.03
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet (2009) 6.99
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92
Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology (2008) 6.75
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis (2010) 5.85
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78
Pathogenesis of liver fibrosis. Annu Rev Pathol (2011) 5.27
Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol (2008) 5.24
Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol (2006) 5.17
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05
Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology (2002) 4.83
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature (2011) 4.57
Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell (2009) 4.30
Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. J Hepatol (2013) 4.28
Functional copy-number alterations in cancer. PLoS One (2008) 4.27
Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A (2011) 4.15
miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A (2009) 4.15
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis (2007) 3.75
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol (2013) 3.71
Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology (2015) 3.63
CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest (2009) 3.62
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Focus on hepatocellular carcinoma. Cancer Cell (2004) 3.49
A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44